Thermal laser treatment in AMD: Therapeutic and prophylactic

International Ophthalmology Clinics

Volumn 47, Issue 1, 2007, Pages 75-93

  Cukras, Catherine ^a   Fine, Stuart L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN; ZINC;

CLINICAL PRACTICE; DIET SUPPLEMENTATION; DISEASE COURSE; DRUSEN; HUMAN; LASER COAGULATION; LOW LEVEL LASER THERAPY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROPHYLAXIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

CHOROIDAL NEOVASCULARIZATION; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; TREATMENT OUTCOME;

EID: 33846475583     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31802bda65     Document Type: Review

References (63)

1. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
2. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;80:9-14.
3. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205-210.
4. Klein R, Klein BE, Jensen SC, et al. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104:7-21.
5. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24(suppl):335-610.
6. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
7. Hyman LG, Lilienfeld AM, Ferris FL III, et al. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118:213-227.
8. Pauleikhoff D. Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina. 2005;25:1065-1084.
9. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
10. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114.
11. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100:912-918.
12. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol. 1982;93:157-163.
13. Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions. Results of a randomized clinical trial. Arch Ophthalmol. 1990;108:832-837.
14. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol. 1994;112:500-509.
15. Guyer DR, Fine SL, Maguire MG, et al. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986;104:702-705.
16. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol. 1999;117:1329-1345.
17. Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1347-1357.
18. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1358-1361.
19. The Moorfields Macular Study Group. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. Br J Ophthalmol. 1982;66:745-753.
20. Coscas G, Soubrane G. Argon laser photocoagulation of subretinal neovascularization in senile macular degeneration. Results of a randomized study of 60 cases. Bull Mem Soc Fr Ophtalmol. 1982;94:149-154.
21. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol. 1993;111:1200-1209.
22. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
23. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1232-1241.
24. Yoken J, Duncan JL, Berger JW, et al. Laser photocoagulation for choroidal neovascularization in age-related macular degeneration. In: Lim JI, ed. Age-Related Macular Degeneration. New York: Marcel Dekker; 2002:181-201.
25. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998;43:134-146.
26. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-791.
27. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol. 1990;108:825-831.
28. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994;112:489-499.
29. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503-512.
30. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115:741-747.
31. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
32. Bressler SB, Maguire MG, Bressler NM, et al. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:1442-1447.
33. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123:1570-1574.
34. Hsu J, Maguire MG, Fine SL. Laser prophylaxis for age-related macular degeneration. Can J Ophthalmol. 2005;40:320-331.
35. Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology. 1994;101:1522-1528.
36. Gass JD. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:580-608.
37. Gass JD. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90:206-217.
38. Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology. 1991;98:1379-1383.
39. Figueroa MS, Regueras A, Bertrand J. Laser photocoagulation to treat macular soft drusen in age-related macular degeneration. Retina. 1994;14:391-396.
40. Figueroa MS, Regueras A, Bertrand J, et al. Laser photocoagulation for macular soft drusen. Updated results. Retina. 1997;17:378-384.
41. Bressler NM, Munoz B, Maguire MG, et al. Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. Arch Ophthalmol. 1995;113:301-308.
42. Ho AC, Maguire MG, Yoken J, et al. Laser-induced drusen reduction improves visual function at 1 year. Choroidal Neovascularization Prevention Trial Research Group. Ophthalmology. 1999;106:1367-1373; discussion 1374.
43. Duvall J, Tso MO. Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. Arch Ophthalmol. 1985;103:694-703.
44. Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology. 1997;104:623-631.
45. Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. Br J Ophthalmol. 1998;82:1169-1174.
46. Glaser BM, Campochiaro PA, Davis JL Jr, et al. Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol. 1985;103:1870-1875.
47. Yoshimura N, Matsumoto M, Shimizu H, et al. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest Ophthalmol Vis Sci. 1995;36:1686-1691.
48. Cleasby GW, Nakanishi AS, Norris JL. Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report. Mod Probl Ophthalmol. 1979;20:141-147.
49. Wetzig PC. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Ophthalmol Soc. 1988;86:276-290.
50. Wetzig PC. Photocoagulation of drusen-related macular degeneration: a long-term outcome. Trans Am Ophthalmol Soc. 1994;92:299-303; discussion 303-306.
51. Olk RJ, Friberg TR, Stickney KL, et al. Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology. 1999;106:2082-2090.
52. Scorolli L, Corazza D, Morara M, et al. Argon laser versus subthreshold infrared (810-nm) diode laser macular grid photocoagulation in nonexudative age-related macular degeneration. Can J Ophthalmol. 2003;38:489-495.
53. The Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. Ophthalmology. 1998;105:1364-1372.
54. The Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. Ophthalmology. 1998;105:11-23.
55. The Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology. 2003;110:971-978.
56. Kaiser RS, Berger JW, Maguire MG, et al. Laser burn intensity and the risk for choroidal neovascularization in the CNVPT Fellow Eye Study. Arch Ophthalmol. 2001;119:826-832.
57. Owens SL, Bunce C, Brannon AJ, et al. Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis. Eye. 2003;17:623-627.
58. Owens SL, Bunce C, Brannon AJ, et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol. 2006;141:276-281.
59. Rodanant N, Friberg TR, Cheng L, et al. Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration. Am J Ophthalmol. 2002;134:577-585.
60. Friberg TR, Musch DC, Lim JI, et al. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology. 2006;113:622e1.
61. Friberg TR. PTAMD Study Group. The Prophylactic Treatment of AMD Multi-Centered Trial (PTAMD): Results From the Bilateral Study Arm. in ARVO. FL: Fort Lauderdale; 2006.
62. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials. 2004;1:91-107.
63. Prenner JL, Rosenblatt BJ, Tolentino MJ, et al. Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina. 2003;23:307-314.